CN110088108B - 取代的吡唑并氮杂䓬-4-酮类及其作为磷酸二酯酶抑制剂的用途 - Google Patents

取代的吡唑并氮杂䓬-4-酮类及其作为磷酸二酯酶抑制剂的用途 Download PDF

Info

Publication number
CN110088108B
CN110088108B CN201680091502.7A CN201680091502A CN110088108B CN 110088108 B CN110088108 B CN 110088108B CN 201680091502 A CN201680091502 A CN 201680091502A CN 110088108 B CN110088108 B CN 110088108B
Authority
CN
China
Prior art keywords
ethyl
tetrahydropyran
spiro
dihydro
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680091502.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN110088108A (zh
Inventor
梁锡福
J·拉森
S·F·尼尔森
P·安德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Combination Therapy Co
Original Assignee
Combination Therapy Co
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combination Therapy Co, Leo Pharma AS filed Critical Combination Therapy Co
Publication of CN110088108A publication Critical patent/CN110088108A/zh
Application granted granted Critical
Publication of CN110088108B publication Critical patent/CN110088108B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201680091502.7A 2016-12-12 2016-12-12 取代的吡唑并氮杂䓬-4-酮类及其作为磷酸二酯酶抑制剂的用途 Expired - Fee Related CN110088108B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2016/080548 WO2018108230A1 (en) 2016-12-12 2016-12-12 Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors

Publications (2)

Publication Number Publication Date
CN110088108A CN110088108A (zh) 2019-08-02
CN110088108B true CN110088108B (zh) 2024-06-14

Family

ID=57539258

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680091502.7A Expired - Fee Related CN110088108B (zh) 2016-12-12 2016-12-12 取代的吡唑并氮杂䓬-4-酮类及其作为磷酸二酯酶抑制剂的用途

Country Status (8)

Country Link
US (1) US10906915B2 (https=)
EP (1) EP3551633B1 (https=)
JP (1) JP6850886B2 (https=)
CN (1) CN110088108B (https=)
DK (1) DK3551633T3 (https=)
ES (1) ES2875128T3 (https=)
RU (1) RU2762279C2 (https=)
WO (1) WO2018108230A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3551632B1 (en) * 2016-12-12 2024-06-12 UNION therapeutics A/S Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors
DK3642210T3 (da) 2017-06-20 2024-12-09 Union Therapeutics As Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
PT3724196T (pt) 2017-12-15 2023-01-13 Union Therapeutics As Azetidina di-hidrotienopiridinas substituídas e a sua utilização como inibidores de fosfodiesterase
GB202306662D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Dosage regimen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104175A2 (en) * 2007-02-28 2008-09-04 Leo Pharma A/S Novel phosphodiesterase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2803299B1 (fr) * 2000-01-05 2004-09-17 Warner Lambert Co NOUVELLES PYRAZOLO [4,3-e] DIAZEPINES SUBSTITUEES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
WO2004098520A2 (en) 2003-05-01 2004-11-18 Irm Llc Compounds and compositions as protein kinase inhibitors
TW200745106A (en) * 2005-10-03 2007-12-16 Astrazeneca Ab Chemical compounds
ES2372320T3 (es) 2006-11-15 2012-01-18 Vertex Pharmceuticals Incorporated Compuestos útiles como inhibidores de proteínas quinasas.
GB0704652D0 (en) 2007-03-09 2007-04-18 Syngenta Participations Ag Novel herbicides
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104175A2 (en) * 2007-02-28 2008-09-04 Leo Pharma A/S Novel phosphodiesterase inhibitors

Also Published As

Publication number Publication date
CN110088108A (zh) 2019-08-02
RU2019121006A (ru) 2021-01-12
US20200010477A1 (en) 2020-01-09
US10906915B2 (en) 2021-02-02
RU2019121006A3 (https=) 2021-01-12
JP6850886B2 (ja) 2021-03-31
JP2020500920A (ja) 2020-01-16
DK3551633T3 (da) 2021-06-28
RU2762279C2 (ru) 2021-12-17
EP3551633A1 (en) 2019-10-16
EP3551633B1 (en) 2021-03-31
ES2875128T3 (es) 2021-11-08
WO2018108230A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
EP3724194B1 (en) Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
CN111712503B (zh) 取代的四氢吡喃二氢噻吩并嘧啶类化合物及其作为磷酸二酯酶抑制剂的用途
CN110088108B (zh) 取代的吡唑并氮杂䓬-4-酮类及其作为磷酸二酯酶抑制剂的用途
EP3724196B1 (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
CN110099905B (zh) 取代的吡唑并氮杂䓬-8-酮类及其作为磷酸二酯酶抑制剂的用途
CN110167944B (zh) 取代的吡唑并氮杂䓬-4-酮类及其作为磷酸二酯酶抑制剂的用途
HK40041147A (en) Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
HK40041147B (en) Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
HK40039957A (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
HK40039957B (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
HK40041148B (en) Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
HK40041148A (en) Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210706

Address after: Dane Heller Rupp

Applicant after: Combination therapy Co.

Address before: Denmark and Rupp

Applicant before: LEO PHARMA A/S

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20240614